Detalhe da pesquisa
1.
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
Clin Infect Dis
; 76(3): e910-e919, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35861296
2.
Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study Protocol.
medRxiv
; 2024 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38853861
3.
"It is not easy": Experiences of people living with HIV and tuberculosis on Tuberculosis treatment in Uganda.
J Clin Tuberc Other Mycobact Dis
; 33: 100385, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38116575
4.
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Trials
; 21(1): 181, 2020 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32054536